» Articles » PMID: 38538742

Ultra High Content Analyses of Circulating and Tumor Associated Hybrid Cells Reveal Phenotypic Heterogeneity

Overview
Journal Sci Rep
Specialty Science
Date 2024 Mar 28
PMID 38538742
Authors
Affiliations
Soon will be listed here.
Abstract

Persistently high, worldwide mortality from cancer highlights the unresolved challenges of disease surveillance and detection that impact survival. Development of a non-invasive, blood-based biomarker would transform survival from cancer. We demonstrate the functionality of ultra-high content analyses of a newly identified population of tumor cells that are hybrids between neoplastic and immune cells in patient matched tumor and peripheral blood specimens. Using oligonucleotide conjugated antibodies (Ab-oligo) permitting cyclic immunofluorescence (cyCIF), we present analyses of phenotypes among tumor and peripheral blood hybrid cells. Interestingly, the majority of circulating hybrid cell (CHC) subpopulations were not identified in tumor-associated hybrids. These results highlight the efficacy of ultra-high content phenotypic analyses using Ab-oligo based cyCIF applied to both tumor and peripheral blood specimens. The combination of a multiplex phenotypic profiling platform that is gentle enough to analyze blood to detect and evaluate disseminated tumor cells represents a novel approach to exploring novel tumor biology and potential utility for developing the population as a blood-based biomarker in cancer.

Citing Articles

Cell fusion as a driver of metastasis: re-evaluating an old hypothesis in the age of cancer heterogeneity.

Lopez-Collazo E, Hurtado-Navarro L Front Immunol. 2025; 16:1524781.

PMID: 39967663 PMC: 11832717. DOI: 10.3389/fimmu.2025.1524781.


Circulating Neoplastic-Immune Hybrid Cells Are Biomarkers of Occult Metastasis and Treatment Response in Pancreatic Cancer.

Patel R, Parappilly M, Farley H, Latour E, Wang L, Nair A Cancers (Basel). 2024; 16(21).

PMID: 39518088 PMC: 11545756. DOI: 10.3390/cancers16213650.


Tumor-immune hybrid cells evade the immune response and potentiate colorectal cancer metastasis through CTLA4.

Tanjak P, Chaiboonchoe A, Suwatthanarak T, Thanormjit K, Acharayothin O, Chanthercrob J Clin Exp Med. 2024; 25(1):2.

PMID: 39499374 PMC: 11538261. DOI: 10.1007/s10238-024-01515-9.

References
1.
Toyoshima K, Hayashi A, Kashiwagi M, Hayashi N, Iwatsuki M, Ishimoto T . Analysis of circulating tumor cells derived from advanced gastric cancer. Int J Cancer. 2015; 137(4):991-8. DOI: 10.1002/ijc.29455. View

2.
Lustberg M, Balasubramanian P, Miller B, Garcia-Villa A, Deighan C, Wu Y . Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients. Breast Cancer Res. 2014; 16(2):R23. PMC: 4053256. DOI: 10.1186/bcr3622. View

3.
Dietz M, Sutton T, Walker B, Gast C, Zarour L, Sengupta S . Relevance of circulating hybrid cells as a non-invasive biomarker for myriad solid tumors. Sci Rep. 2021; 11(1):13630. PMC: 8249418. DOI: 10.1038/s41598-021-93053-7. View

4.
Wang Y, Woehrstein J, Donoghue N, Dai M, Avendano M, Schackmann R . Rapid Sequential in Situ Multiplexing with DNA Exchange Imaging in Neuronal Cells and Tissues. Nano Lett. 2017; 17(10):6131-6139. PMC: 5658129. DOI: 10.1021/acs.nanolett.7b02716. View

5.
Takao M, Takeda K . Enumeration, characterization, and collection of intact circulating tumor cells by cross contamination-free flow cytometry. Cytometry A. 2011; 79(2):107-17. DOI: 10.1002/cyto.a.21014. View